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Failure  to  repair  DNA  double-stranded  breaks  leads  to  cell  death.  Radiation  therapy  is  
commonly  used  to  kill  cancer  cells  by  inducing  these  breaks.  However  resistance  to  radiation  
therapy,  due  to  a  hyperactive  DNA  double-stranded  break  repair  pathway,  is  a  common  
occurrence  that  makes  cancer  patients  more  prone  to  relapse.  The  Shieldin  complex  is  shown  to  
promote  DNA-double  stranded  break  repair  by  binding  to  DNA  at  sites  of  damage.  Thus,  the  
objective  of  this  project  is  to  understand  the  affinity  and  type  of  DNA  that  Shieldin  binds  to,  
through  gel-shift  assays  and  computational  modeling,  for  the  eventual  creation  of  an  inhibitor  for  






More  than  14  million  new  cases  of  cancer  are  diagnosed  globally  each  year,  and  over  
50%  of  these  patients  will  undergo  radiation  therapy  (RT)  [1].  RT  induces  
DNA  double-stranded  breaks  (DSBs),  a  cut  through  both  sides  of  the  DNA  
backbone  resulting  in  DNA  overhangs  (Fig.  1)  [2].  By  creating  DSBs,  RT  
overwhelms  cancer  cells  by  blocking  the  progression  of  DNA  replication  and  
causing  chromosomal  translocations  which  creates  genomic  instability  [2].   
Unfortunately,  resistance  to  RT  is  observed  within  cancer  cells  due  to  an  upregulation  of  
DSB  repair  pathways  [3].  As  a  result,  the  creation  of  chemotherapeutics  that  target  DSB  repair  
pathway  machinery  can  inhibit  cancer  cell’s  ability  to  become  
radioresistant.   
 Our  cells  have  two  predominant  pathways  to  repair  DSBs:  
Homologous  Recombination  (HR)  and  Nonhomologous  End-Joining  
(NHEJ).  NHEJ  accounts  for  almost  75%  of  DSB  repairs  and  works  by  
ligating/joining  DSB  blunt  ends  (Fig.  2).  However,  NHEJ  inaccurately  
repairs  DSBs  by  deleting  DNA  ends  (Fig.  2),  thus  inducing  mutagenesis  
that  may  contribute  to  carcinogenesis  [4].   
 NHEJ  plays  a  key  role  in  radioresistant  cancer  cells  since  many   
proteins  specific  to  NHEJ  are  over-expressed  [5].  Furthermore,  due  to  its  
error-prone  repair  of  DSBs  (Fig.  2),  NHEJ  enables  cancer  cells  to  
accumulate  mutations,  further  contributing  to  a  radioresistant  phenotype.  Consequently,  proteins  
involved  in  NHEJ  are  potential  chemotherapeutic  targets  to  impair  the  hyperactivity  of  this  
pathway  in  radioresistant  cancer  cells,  thus  making  them  more  susceptible  to  RT.  This  has  
  
previously  been  attempted  by  creating  inhibitors  for  major  NHEJ  proteins  such  as  DNA-PKcs  or  
DNA  Ligase  IV.  However,  these  inhibitors  had  poor  specificity  and  in  vivo  toxicity  hence  
preventing  clinical  application  [6].  Therefore,  identifying  new  chemotherapeutic  targets  within  
NHEJ  is  necessary.   
A  newly  discovered  protein,  the  Shieldin  (SHLD)  complex,  promotes  NHEJ  by  binding  
to  DNA  at  sites  of  DSBs  through  three  OB-fold  domains  on  its  SHLD2  subunit  [7].  By  
interacting  with  DNA,  SHLD  acts  downstream  of  53BP1  and  RIF1  to  create  the  DNA  blunt  ends  
necessary  for  NHEJ.  SHLD  prevents  exo-  and  endonucleases  involved  in  HR  from  resecting  
(cutting  away  nucleotides)  DNA  ends  which  precludes  HR  from  dominating  [8].  
SHLD  is  overexpressed  in  prostate  and  triple-negative  breast  cancer  patients  allowing  for  
a  hyperactive  NHEJ  pathway  [10].  SHLD  also  plays  a  key  role  in  the  fusion  of  deprived  
telomeres  characterized  by  a  repetitive  sequence  of  DNA  at  the  ends  of  chromosomes  that  look  
like  damaged  DNA,  due  to  the  presence  of  DNA  overhangs.  This  has  a  causative  role  in  
promoting  genomic  instability  in  colon  and  ovarian  cancer  tumors.  Genetic  screens  have 
identified  SHLD  as  a  promoter  of  radioresistance  in  cancer  cells  since  it  localizes  to  DSBs  
induced  by  RT.  Furthermore,  knockout  studies  report  SHLD  depleted  breast  cancer  cells  are  
hypersensitive  to  RT  induced  DSBs  [9].  Together,  this  data  suggests  that  inhibiting  SHLD’s  
ability  to  bind  to  DNA  could  create  cancer  cells  sensitized  to  RT.  
SHLD  binds  DNA  through  the  SHLD2  subunit.  In  order  to  create  small  molecule  
inhibitors  for  SHLD2,  to  impair  NHEJ  and  prevent  the  onset  of  radioresistance  in  cancer  cells,  it  
must  be  further  understood.  One  gap  in  knowledge  is  SHLD2’s  preferred  DNA  substrate  (the  
type  of  DNA  SHLD2  binds  to  at  DSBs).  Studies  that  have  tried  to  identify  this  are  inconsistent  in  
their  findings.  Findlay  et  al.  report  that  SHLD2  is  proficient  in  equally  binding  to  both  dsDNA  
  
and  ssDNA  [9],  while  Gao  et  al.  claim  SHLD2  binds  to  dsDNA  with  a  higher  affinity  for  ssDNA  
[11].  More  importantly,  overhang  DNA,  typically  found  at  DSBs  (Fig.  1),  and  sequence  
repetitive  DNA  is  yet  to  be  tested.   
Methods:  
Cell  Culture  -  
4  mL  of  LB  was  inoculated  with  a  colony  of  cells  from  the  LB  agar  plate  and  4  μL  of  the  
respective  antibiotic.  The  tube  was  placed  in  a  shaker  at  37°C  overnight.   
Plasmid  Prep  -   
Cells  grown  from  a  4  mL  culture  were  formed  into  a  cell  pellet  in  a  2  mL  eppendorf  tube  
using  a  microcentrifuge  set  to  11,000  rcf  for  1  minute.  The  cell  pellet  was  resuspended  in  A1  
Buffer  from  the  NucleoSpin  Plasmid  Prep  Kit  and  lysed  using  the  A2  buffer.  The  A2  lysis  buffer  
solubilizes  the  cell  membrane  allowing  the  cell  material  (hence  the  plasmid)  to  be  released.  The  
lysis  buffer  is  neutralized  using  the  A3  buffer  and  spun  down  in  the  microcentrifuge  for  20  
minutes  to  separate  the  soluble  and  insoluble  factions  of  the  cell  lysate.  The  soluble  fraction  
(which  contains  the  plasmid)  is  loaded  onto  a  silica  membrane  column  and  washed  several  times  
with  the  AW  and  A4  wash  buffers  and  finally  50  μL  of  elution  was  captured  using  the  AE  buffer.  
A  1:10  dilution  was  created  by  diluting  10  μL  of  the  elution  into  90  μL  of  Milli-Q  water.  The  280  
nm  absorbance  of  the  dilution  was  reate  using  an  OD  spectrophotometer  to  read  the  contectration  
of  the  DNA  in  ng/μL  and  to  assess  the  purity  of  the  elution.   
DNA  Sequencing  -   
In  order  to  determine  if  the  plasmid  contains  the  right  sequence,  teo  samples  per  plasmid  
stock  were  created  each  with  a  concentration  of  80  ng/μL.  One  sample  added  5  μL  of  
petUpstream  primer  (SEQ)  and  the  other  sample  added  the  T7-term  primer  (5’  
  
GCTAGTTATTGCTCAGCGG  3’).  These  primers  bind  to  the  respective  parts  of  the  plasmid  to  
help  with  sequencing.  The  two  samples  were  sent  to  Genewiz  for  DNA  sequencing.   
Primer  Dilutions  -   
Primers  were  ordered  for  IDT  in  a  lyophilized  pellet.  The  amount  of  Milli-Q  water  added  
to  resuspend  the  primers  was  determined  using  the  following  equation:  [(mg*1000)*6000]/MW.  
A  1:10  dilution  of  the  primer  stock  was  done  for  later  use.  
Polymerase  Chain  Reaction  (PCR)  -  
200  μL  PCR  tubes  consisted  of  the  following  reagents:  25  μL  of  Master  Mix,  1.5μL  of  
forward  primer,  1.5μL  of  reverse  primer,  1μL  of  template  at  a  5ng/μL  concentration,  and  21μL  of  
Milli-Q.  To  check  if  PCR  worked,  a  0.85%  agarose  gel  was  prepared  by  dissolving  2μL  of  SYBR  
Safe  and  0.3  grams  agarose  into  35  mL  of  0.5X  TAE  buffer  (Included  cycle  settings).  The  gel  
was  then  poured  into  a  tray  with  a  gel  comb  and  polymerized  at  room  temperature  for  15  
minutes.  Samples  for  the  agarose  gel  were  prepared  by  mixing  10  μL  of  the  final  PCR  mix  with  
2  μL  of  6X  Purple  Loading  Dye.  The  samples  were  then  loaded  onto  the  agarose  gel  and  run  for  
approximately  20  minutes  after  which  the  gel  was  imaged  under  a  UV  light.   
Cell  Transformation  -   
5  μL  of  a  5ng/uL  plasmid  stock  were  pipetted  into  competent  BL21  cells  and  incubated  
on  ice  for  25  minutes.  The  cells  were  then  heat  shocked  for  45  seconds  at  42°C  and  then  placed  
on  ice  for  2  minutes.  The  heat  shocked  cells  were  then  mixed  in  500  μL  LB  for  1  hour  at  37°C  
with  shaking  and  then  spread  onto  an  LB  agar  plate  with  the  respective  antibiotic.  The  plate  was  





Plasmid  Cloning  -   
The  insert  is  amplified  through  PCR.  Both  the  insert  and  the  empty  plasmid  are  digested  
using  reaction  enzymes  with  the  following  regents:  20  μL  CutSmart  Buffer,  10  μL  plasmid  or  
insert,  4  μL  Xhol,  4  μL  BamH,  62  μL  Milli-Q  for  a  total  of  100  μL.  Then  the  sample  was  cleaned  
using  a  PCR  prep  kit  and  only  the  plasmid  was  dephosphorylated  using  2  μL  of  rSAP  and  
incubated  at  37°C  for  30  minutes  and  then  at  70°C  for  20  minutes.  The  dephosphorylated  
plasmid  sample  was  cleaned  using  a  PCR  Prep  kit  and  then  both  the  insert  and  vector  were  
ligated  using  2  μL  of  T4  DNA  Ligase  Buffer,  1  μL  of  the  insert,  2  μL  of  the  vector,  1  μL  of  T4  
DNA  Ligase,  and  14  μL  of  Milli-Q.  The  ligation  was  run  overnight  and  all  20  μL  of  the  ligated  
plasmid  sample  was  transformed  into  BL12  cells  using  the  transformation  protocol.  Colonies  
from  the  transformation  were  cultured  overnight  in  4  mL  and  then  plasmid  prepped  to  extract  the  
ligated  plasmid  and  sent  for  DNA  sequencing  to  confirm  correct  sequence.   
Site-Directed  Mutagenesis   -  
Primers  were  designed  to  either  delete  parts  of  a  protein  sequence  or  to  create  a  mutation  
within  a  protein  sequence  by  targeting  specific  sequences  within  a  plasmid  (more  detail  about  the  
specific  primers  is  in  the  results  section).  First  the  PCR  protocol  was  used  to  amplify  the  specific  
part  of  the  plasmid  that  was  of  interest.  The  amplified  DNA  was  phosphorylated  using  20  μL  of  
Milli-Q,  2.5  μL  of  T4  DNA  ligase  buffer,  2  μL  of  the  PCR  mix,  and  0.5  μL  of  T4  PNK.  This  
reaction  was  incubated  at  37°C  for  30  minutes  and  then  at  70°C  for  20  minutes.  The  
phosphorylated  was  then  ligated  using  13.5  μL  of  Milli-Q,  3.5  μL  of  the  phosphorylated  DNA,  2  
μL  of  T4  DNA  Ligase  buffer,  and  1  μL  of  DNA  ligase.  The  ligation  was  run  for  3-5  hours  and  
all  20  μL  of  the  ligated  plasmid  sample  was  transformed  into  BL12  cells  using  the  
  
transformation  protocol.  Colonies  from  the  transformation  were  cultured  overnight  in  4  mL  and  
then  plasmid  prepped  to  extract  the  ligated  plasmid  and  sent  for  DNA  sequencing  to  confirm  
correct  sequence.   
Protein  Purification  -   
Transformed  cells  were  cultured  into  1L  and  then  spun  down  at  6000  rpm  with  a  
centrifuge  to  pellet  the  cells.  The  cell  pellet  is  then  resuspended  into  a  1x  Lysis  buffer.  300μL  of  
Triton-X,  300μL  of  PMSF,  and  a  dash  of  lysozyme  is  added  to  the  cell  resuspension  which  is  
then  sonicated  at  15  seconds  on  and  45  seconds  off  on  ice.  The  resulting  cell  lysate  is  spun  down  
at  15000  rpm  with  a  centrifuge.  The  supertanted  is  then  filtered  through  a  0.45μM  filter  into  a  
cobalt  matrix  column.  The  column  is  then  placed  at  4 o C  for  25  minutes  with  shaking.  The  
solution  then  flows  through  the  column  and  the  matrix  is  washed  several  times  (approx.  4)  with  
1x  Lysis  buffer  and  then  the  protein  is  eluted  from  the  matrix  using  an  elution  buffer.  The  elution  
is  then  concentrated  down  to  5mL  using  the  respective  Amicon  tube  and  loaded  onto  the  FPLC  
with  an  FPLC  buffer  (20  mM  Tris,  100mM  NaCl,  1mM  DTT,  2mM  EDTA,  pH  8.5)  for  size  
exclusion  chromatography.   
EMSA-   
12  binding  reactions  of  varying  concentrations  of  protein  were  created  into  20μL.  The  
concentration  of  DNA  remained  the  same  while  the  concentration  of  protein  increased.  Varying  
amounts  of  5x  Binding  Buffer  (50  µL  of  1  M  Tris-HCl,  pH  7.5;  10  µL  of  5  M  NaCl;  200  µL  of  1  
M  KCl,  5  µL  of  1  M  MgCl2,  10  µL  of  0.5  M  EDTA,  pH  8.0;  5  µL  of  1  M  DTT;  25  µL  of  10  
mg/mL  BSA,  and  695  µL  of  ddH2O  [12]).  and  glycerol  were  added  to  maintain  the  20μL  total  
volume.  Before  loading  onto  a  polyacrylamide  gel,  4μL  of  6x  EMSA  loading  dye  was  added  to  
solution  and  20μL  of  the  total  solution  was  loaded  into  the  gel.  The  gel  was  then  run  for  5-6  
  
hours  at  110V  in  a  1x  TBE  buffer  (  89  mM  Tris  base,  89  mM  boric  acid,  1  mM  EDTA,  pH  ~8.0).  
The  gel  was  then  stained  for  DNA  diluting  10000X  Sybr  Safe  in  1x  TBE  buffer  with  5μL  and  
was  left  shaking  for  45  minutes.  The  gel  was  then  imaged  under  UV  light.   
  
Results:  
Plasmids  -  
In  order  to  carry  out  any  structural  studies  on  SHLD2’s  OB  fold  domains,  plasmid  
construct  encodes  the  sequence  of  the  OB-folds  were  created.   
A  plasmid  is  a  small  circular  double-stranded  DNA  that  is  separate  from  chromosomal  
DNA.  Plasmids  contain  different  parts  as  shown  in  Figure  1  below.  The  most  important  aspects  
of  a  plasmid  relevant  for  this  study  are  the  inserted  gene  and  the  antibiotic  resistance  gene.  The  
inserted  gene  encodes  the  sequence  of  a  
subdomain  of  SHLD2  C-terminus  OB-folds.  
Because  this  gene  is  inserted  downstream  of  the 
promoter,  the  gene  will  be  expressed  within  the  
BL21  E.  Coli  cells  that  are  transformed  with  the  
plasmid.  The  antibiotic  resistance  gene  allows 
for  the  
selection  of  cells  that  have  this  plasmid.  Though  cells  
are  transformed  to  take  up  the  plasmid,  not  all  of  them  
might  have  it,  as  a  result  growing  cell  cultures  with  the  
presence  of  an  antibiotic  that  the  plasmid  confers  
  
resistance  to  can  kill  any  cells  that  do  not  have  the  plasmid.   
The  plasmid  used  in  this  study  is  the  pETDuet  vector  shown  in  Figure  2.  This  plasmid  
has  an  ampicillin  resistance  gene  allowing  ampicillin  to  be  used  as  a  selective  marker.  The  
pETDuet  vector  expresses  protein  with  a  His-tag  on  the  N-terminus  (six  histidines  at  the  very  
beginning  of  the  protein’s  primary  sequence).  The  significance  of  this  His-tag  is  discussed  in  the  
protein  purification  section  of  this  report.   
OB1:  
The  plasmid  that  encodes  SHLD2  OB1  was  already  in  the  lab,  however  it  was  
resequenced.  In  order  to  accomplish  this  the  OB1  plasmid  was  transformed  into  Top10  E.  Coli  
cells.   
Colonies  from  the  plate  of  transformed  Top10  cells  were  cultured  into  4  mL  and  plasmid  
prepped  using  the  NucleoSpin  Plasmid  Prep  Kit.  The  concentration  of  OB1  extracted  was  968  
ng/μL.  To  prepare  samples  for  DNA  sequencing,  two  samples  each  with  a  concentration  of  80 
ng/μL  of  plasmid  were  made.  When  reading  the  sequence  of  the  plasmid,  only  the  sequence  of  
the  inserted  gene  is  of  interest  since  this  is  where  the  sequence  encoding  OB1  is.  To  make  sure  
not  the  whole  plasmid  is  sequenced  and  only  the  inserted  gene  is,  one  of  the  two  samples  read  
the  sequence  in  the  forward  (5’-3’)  direction  and  the  other  sample  would  read  the  sequence  in  the  
reverse  (3’-5’)  direction.  5μL  of  a  pETUpstream  primer  at  a  concentration  of  166.7  μM  was  
added  to  the  forward  sample.  The  sequence  of  the  pETUpstream  primer  is  5’  
ATGCGTCCGGCGTAG  3’  which  binds  right  before  the  sequence  of  the  OB1  gene  allowing  for  
sequencing  results  to  be  read  in  the  5’-3’  direction.  The  T7-term  primer  is  added  to  the  reverse  
sample  which  binds  near  the  end  of  the  OB1  gene  on  the  plasmid  allowing  for  sequencing  results  
to  be  read  in  the  3’-5’  direction.  The  two  samples  were  sent  to  Genewiz  for  sequencing  results.  
  
Figure  3a  and  3b  show  the  forward  and  reverse  sequencing  results  respectively.  Both  
sequences  were  translated  into  an  amino  acid  sequence  using  the  ExPASY  translate  tool.  The  
amino  acid  sequence  of  the  inserted  gene  is  shown  in  Figure  3c.  Using  the  blastp  multiple  protein  
sequence  alignment  software,  this  amino  acid  sequence  was  mapped  to  the  range  427  to  596  on  
the  full  SHLD2  isoform  1  sequence.   
























Figure  3  -  OB1  plasmid  Sequencing  Results  
  
Figure  4  shows  the  secondary  structure  prediction  of  SHLD2  from  the  residue  range  of  
427  to  595.  This  prediction  was  done  using  the  Quick2D  set  on  the  MPI  bioinformatic  Toolkit  
software.  Quick2D  uses  ten  algorithms  to  predict  the  amino  acid  locations  of  α-helices  (red)  and  
  
β-sheets  (blue)  which  are  the  two  primary  components  of  a  protein's  secondary  structure.  
  
From  Figure  4,  it  is  clear  that  there  are  five  β-sheets  followed  by  an  α-helix  marked  down  
in  a  black  box.  These  ranges  are  important  because  they  represent  the  secondary  structure  
components  of  an  OB-fold  at  the  general  level  which  is  a  five-stranded  β  barrel  with  one  end  
capped  by  an  α-helix.   
Both  the  sequencing  results  and  the  secondary  structure  prediction  of  the  mapped  region  
on  SHLD2’s  amino  acid  sequence  show  that  the  plasmid  correctly  encodes  the  sequence  of  first  
DNA  binding  domain  on  SHLD2.  
OB2:  
Like  OB1,  the  plasmid  encoding  SHLD2  OB2  was  at  the  lab  but  was  resequenced.  The  
same  process  used  for  OB1  was  used  to  sequence  OB2.  The  concentration  of  the  OB2  plasmid  
was  906  ng/μL  and  the  DNA  sequencing  samples  were  prepared  and  sent  to  Genewiz  the  same  
way  as  OB1.   














Figure  5  -  OB2  Plasmid  Sequencing  Results  
   
Figure  5a  shows  the  sequencing  results.  The  forward  sequencing  results  are  not  shown  
due  to  poor  sequencing.  The  amino  acid  sequence  translated  from  the  DNA  sequence,  shown  in  
Figure  5c,  was  mapped  to  the  residues  579-707  on  the  full  SHLD2  isoform  1  amino  acid  
  
sequence.  The  secondary  structure  prediction  of  this  residue  range  is  shown  in  Figure  6  clearly  
shows  a  β  barrel  end  capped  by  an  α-helix.  All  of  which  make  up  the  structure  of  an  OB-fold  
This  data  shows  that  the  plasmid  correctly  encodes  the  sequence  of  the  second  OB-fold  of  
the  SHLD2  subunit.  
OB3:  
Like  OB1  and  OB2,  the  plasmid  encoding  SHLD2  OB3  was  at  the  lab  but  was  
resequenced.  The  same  process  used  for  OB1and  OB2  was  used  to  sequence  OB3.  The  
concentration  of  the  OB3  plasmid  was  818  ng/μL  and  the  DNA  sequencing  samples  were  
prepared  and  sent  to  Genewiz  the  same  way  as  OB1  and  OB2.  






















Figure  7  -  OB3  Sequencing  Results   
  
Figure  7a  and  7b  show  the  forward  and  reverse  sequencing  results  respectively.  The  amino  acid  
sequence  resulting  from  translating  the  DNA  sequence  shown  in  Figure  6c  maps  to  the  amino  
acid  range  of  764-897  of  SHLD2.  
Figure  8  shows  the  secondary  structure  prediction  of  this  residue  range.  Though  the  key  
features  of  an  OB-fold  secondary  structure  are  not  as  apparent  as  OB1  and  OB2  it  is  not  as  
obvious  in  OB3.  The  implications  of  this  are  further  discussed  during  the  purification  of  OB3.  
  
OB123:  
To  make  the  plasmid  that  encodes  the  full  C-terminus  OB-folds  of  SHLD2,  the  plasmid  
cloning  protocol  described  in  the  methods  section  was  used.  Figure  9a  briefly  describes  how  
cloning  works.   
First  an  empty  vector  and  a  
target  gene  are  acquired.  For  the  
creation  of  the  OB123  plasmid,  an  
empty  pETDuet  vector  was  used  
and  a  dsDNA  fragment  that  
  
encoded  the  sequence  of  SHLD2  OB123  was  used  as  the  target  gene.   
From  Figure  2,  it  is  clear  that  the  pETDuet  vector  has  many  restriction  enzyme  cut  sites.  
A  restriction  enzyme  cleaves  dsDNA  at  specific  sites/sequences.  The  restriction  enzymes  used  
were  BamHI  and  XhoI.  Figure  9b  shows  the  dsDNA  cute  site  that  these  enzymes  recognize  and  
how  they  cut  the  dsDNA.  BamHI  and  XhoI  generate  DNA  sticky  ends  when  cutting  dsDNA.  
Sticky  ends  refers  to  the  presence  of  a  few  unpaired  nucleotides  at  the  end  of  dsDNA.  This  is  
important  because  both  the  empty  pETDuet  vector  and  the  OB123  DNA  fragment  each  contain  a  
BamHI  and  XhoI  recognition  site.  As  a  result,  the  OB123  fragment  and  the  empty  pETDuet  
vector  have  compatible  DNA  sticky  ends.  Figure  12  better  represents  this  crucial  idea.  When  two  
fragments  of  DNA  are  cut  by  the  same  restriction  enzyme  their  sticky  ends  are  complementary.   
To  accomplish  this  the  OB123  DNA  insert  was  amplified  through  PCR,  and  the  empty  
vector  and  insert  were  digested  with  BamHI  and  XhoI.   
The  plasmid  only  was  then  dephosphorylated  using  Shrimp  Alkaline  Phosphatase  (rSAP).  
When  digesting  the  plasmid,  the  5’  ends  still  remain  phosphorylated,  thus  allowing  the  plasmid  
to  re-circulize  without  the  inserted  gene.  By  dephosphorylating  the  plasmid,  rSAP  removes  the  
phosphate  groups  attached  to  the  5’  ends  of  the  plasmid  DNA.   
However  the  phosphate  groups  still  remain  on  the  5’  ends  of  the  OB123  fragment  after  
digestion,  the  fragment  can  be  inserted  into  the  plasmid  through  the  use  of  T4  DNA  ligase.  
Figure  10  shows  how  DNA  
ligase  accomplishes  this.  DNA  
ligase  forms  a  phosphodiester  
bond  between  the  3’  hydroxyl  
  
group  of  the  plasmid  and  the  5’  phosphate  of  the  insert.  

































Figure  11  -  OB123  Sequencing  Results  
  
After  the  dephosphorylated  plasmid  was  ligated  with  the  OB123  insert,  it  was  transformed  into  
Top10  cells  and  colonies  from  the  plate  were  cultured  into  4  mL  and  plasmid  prepped  using  the  
  
NucleoSpin  Plasmid  Prep  Kit.  The  concentration  of  the  extracted  OB123  plasmid  was  91  ng/μL.  
The  DNA  sequencing  samples  were  prepared  the  same  way  as  OB1  and  sent  to  Genewiz  for  
results.   
The  sequence  of  the  OB123  plasmid  is  shown  in  Figure  11.  An  interesting  result  seen  in  
the  sequencing  result  is  that  both  the  forward  and  reverse  sequences  (13a  and  13c  respectively)  
are  different.  This  is  because  the  DNA  sequence  is  too  long  for  both  the  pETUpstream  and  
T7-term  primers  to  read  the  whole  sequence.  Figure  11e  shows  the  full  sequence  of  the  inserted  
gene  which  maps  to  the  range  427-897  on  the  SHLD2  amino  acid  sequence.  This  range  covers  
all  three  OB-fold  domains  thus  confirming  the  successful  creation  of  the  OB123  plasmid.  
OB12:  
The  creation  of  the  OB12  plasmid  used  a  technique  
called  site-directed  mutagenesis.  This  process  can  add  or  
delete  DNA  nucleotides  from  a  plasmid.  By  being  able  
to  add  or  delete  nucleotides,  the  original  amino  acid  
sequence  of  the  plasmid  is  also  altered  because  every  
three  DNA  nucleotides,  called  a  codon,  directly  
translates  into  a  specific  amino  acid.  Since  the  OB123  
plasmid  previously  created  has  the  sequence  for  the  
desired  OB12  plasmid,  this  technique  was  used  to  add  a  
stop  codon  to  the  end  of  OB12  on  the  OB123  plasmid  
(shown  in  red  in  Figure  12).  By  adding  a  stop  codon  (5’  
TAA  3’)  here,  only  OB12  will  be  expressed  from  the  
OB123  plasmid  since  the  codon  terminates  before  OB3  can  be  translated.  
  
To  accomplish  this  PCR  was  first  used  to  amplify  the  DNA  plasmid  that  ,  a  forward  (5’  
AAgttgtattgatcaaagcgcagatt  3’)  and  reverse  (5’  Aaccggaacatttgtcctcc  3’)  primer  were  created  
both  of  which  bound  to  the  end  of  OB2  on  the  OB123  plasmid  (shown  in  red  in  figure  12).  The  
DNA  sequence  highlighted  in  yellow  encoding  the  end  of  OB2  and  the  sequence  highlighted  in  
blue  encoding  the  beginning  of  OB3.  The  primers  are  designed  to  bind  at  this  junction.  The  most  
important  characteristic  of  these  primers  is  that  the  DNA  sequence  (stop-codon)  that  is  being  
inserted  at  this  junction  does  not  bind  to  the  DNA.  However,  these  nucleotides  that  do  not  bind  
get  incorporated  into  the  overall  plasmid  sequence  once  the  DNA  is  replicated.  After  the  primers  
bind  and  are  replicated  within  the  PCR,  the  ends  of  the  primers  that  initially  do  not  bind  are  also  
replicated;  this  results  in  a  long  linear  dsDNA  strand.  To  make  this  linear  DNA  circular  to  form  a  
plasmid  the  5’  ends  were  phosphorylated  using  T4  PNK  and  ligated  using  T4  DNA  ligase.  In  the  
final  result,  notice  that  the  stop  codon  is  right  after  the  end  of  OB2  and  right  before  the  beginning  
of  OB3,  thus  indicating  that  expression  of  the  gene  will  be  terminated  after  translating  OB12.   
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Figure  13  -  OB12  Sequencing  Results  
Figure  13  shows  the  sequencing  of  the  plasmid  after  it  was  extracted  from  a  4mL  culture.  
Like  the  sequencing  results  from  the  OB123  plasmid,  the  forward  and  reverse  sequencing  results  
overlap  with  Figure  16e  showing  the  full  amino  acid  sequence.  The  sequence  maps  to  the  range  
427-724  on  the  full  SHLD2  sequence,  thus  confirming  the  successful  creation  of  the  OB12  
plasmid.   
OB23:  
Site-directed  mutagenesis  was  also  used  in  the  creation  of  the  OB23  plasmid.  
Conceptually  it  is  very  similar  however  instead  of  adding  DNA  nucleotides  to  the  plasmid,  
nucleotides  that  encoded  the  OB1  domain  were  deleted  from  the  OB123  plasmid  through  
specifically  designed  primers.   
The  forward  primer  (5’  CGCGATCTGCCGCCTCG  3’)  binds  to  the  OB123  plasmid  at  
the  end  of  OB1  and  the  reverse  primer  (5’  CTGGCTGTGGTGATGATGGTGATGGC  3’)  binds  
to  the  OB123  plasmid  to  the  beginning  of  OB1.  The  same  process  discussed  above  occurs  which  




































Figure  14  -  OB23  Sequencing  Results  
Figure  14a  and  14b  shows  the  sequencing  results  for  the  forward  and  reverse  primers.  14e  
shows  the  translated  sequence  and  it  maps  to  555-897  of  SHLD2  which  contains  both  OB2  and  
OB3,  thus  confirming  the  successful  creation  of  the  OB23  plasmid.  
  
  
Protein  Purification:  
OB1:  
The  purpose  of  protein  purification  is  to  isolate  a  protein  of  interest  from  all  other  cell  
material.  In  order  to  accomplish  this,  the  plasmid  that  encodes  the  protein,  in  this  case  OB1,  is  
used.  Bacterial  cells  will  take  plasmid  and  express  it  to  produce  the  protein.  One  reason  why  this  
is  important  is  because  human  OB1  is  not  naturally  expressed  in  bacterial  cells,  thus  using  a  
plasmid  allows  for  the  production  of  OB1.  More  importantly,  the  OB1  plasmid  expresses  OB1  
with  a  His-tag  on  its  N-terminus  (six  histidines).  The  sequencing  results  for  OB1  shows  this  in  
Figure  3.  The  significance  of  this  
will  be  discussed  shortly.   
BL21  E.  Coli  cells  were  
transformed  with  the  
pETDuet-OB1  plasmid.  BL21  cells  
are  used  instead  of  Top10  cells  
because  BL21  cells  transcribe  a  
protein  called  T7  RNA  polymerase  
[13].  This  polymerase  helps  
express  other  genes,  like  that  
encoded  on  the  plasmid,  8  times  
faster  than  normal  E.  Coli  cells  
[13].  Furthermore  that  gene  that  
encodes  T7  RNA  polymerase  is  
  
under  control  of  the  lacUV5  promoter  (P  lacUV5),  which  is  a  strong  variant  of  the  wild-type  lac  
promoter  [13],  thus  allowing  for  tight  control  over  when  the  OB1  plasmid  is  expressed.   
A  colony  of  the  transformed  BL21  cells  were  cultured  into  1  L  of  litrobroth  until  the  
OD600  reading  reached  0.8  at  which  point  protein  expression  was  induced  with  
isopropyl-β-D-1-thiogalactopyranoside  IPTG.  By  adding  IPTG,  the  gene  encoding  T7  RNA  
polymerase  is  expressed  and  the  polymerase  recognizes  the  T7  promoters  on  the  pETDuet  
vector,  thus  initiating  the  expression  of  the  protein,  OB1.   
After  induction,  the  cells  were  grown  overnight  and  spun  down  into  a  cell  pellet  using  a  
centrifuge.  The  cells  were  then  resuspended  into  45  mL  of  1x  lysis  buffer.  At  this  point,  the  cells  
should  have  the  OB1  domain  expressed.  This  idea  is  illustrated  in  Figure  15.  This  figure  shows  
an  SDS-PAGE  gel  of  the  different  steps  of  protein  purification  described  in  the  methods  section.  
An  SDS-PAGE  gel  is  used  to  separate  proteins  based  on  molecular  weight,  thus  allowing  for  the  
detection  of  specific  proteins.  Since  the  OB1  domain  is  17.7  kDa,  presence  of  OB1  would  be  
seen  in  the  SDS-PAGE  gel  at  that  molecular  weight.  Lane  3  shows  the  gel  sample  for  the  cell  
culture  before  adding  IPTG.  There  is  clearly  no  band  at  the  17.7  kDa  mark  as  expected  since  
protein  expression  was  not  induced.  However  Lane  4  shows  a  sample  of  the  cell  culture  once  
IPTG  is  added  and  resuspended  in  the  1x  lysis  buffer.  There  is  protein  at  the  17.7  kDa  mark  
which  confirms  protein  induction.   
After  the  cells  were  resuspended,  they  were  sonicated.  Sonication  rupures  cell  
membranes  thus  allowing  for  the  cell  proteins  to  become  released  in  solution.  Lane  5  of  the  gel  
in  figure  15  shows  this  since  there  seems  to  be  more  protein  in  the  lane,  and  protein  is  present  at  
the  17.7  kDa  mark  showing  that  OB1  is  present  in  the  sonicated  cell  lysate.   
  
This  cell  lysate  was  then  spun  down  using  a  centrifuge  set  to  15000  rpm  for  1  hr.  By  
spinning  down  this  lysate,  the  insoluble  and  soluble  fractions  are  separated  by  pelting  the  
insoluble  cell  material.  This  insoluble  material  includes  phospholipids  or  even  
insoluble/aggregated  protein.  Lanes  6  and  7  of  the  gel  show  the  soluble  and  insoluble  fractions  of  
the  spun  down  cell  lysate.  Seeing  that  there  is  a  lot  of  protein  present  in  the  soluble  fraction  
(especially  at  the  17.7  kDa  mark)  shows  that  the  OB1  protein  is  in  the  soluble  fraction.  This  is  
important  because  it  allows  for  the  selective  purification  of  OB1  from  the  soluble  fraction.  OB1  
is  expressed  with  6  histidines  bonded  to  the  N-terminus  of  its  amino  acid  sequence  (refer  to  
sequencing  results  in  Figure  3).  No  other  protein  in  the  soluble  cell  lysate  has  this  type  of  tag  
thus  allowing  the  usage  of  a  method  that  selects  for  proteins  with  the  His-tag  which  is  only  the  
OB1  protein.   
The  method  used  is  called  Immobilized  Metal  Affinity  Chromatography  (IMAC).  IMAC 
is  used  because  purification  of  His-tagged  proteins  by  IMAC  is  based  on  the  affinity  of  histidine 
residues  for  immobilized  metal  ions.  The  cobalt  metal  ion,  Co 2+ ,  is  immobilized  onto  a  
chromatographic  matrix,  as  a  result,  any  His-tag  that  is  in  the  presence  of  this  matrix  will  bind  to  
the  Co 2+  since  histidine  has  a  high  affinity  with  immobilized  metal  ion  matrices,  as  electron   
donor  groups  on  the  histidine  imidazole  ring  readily  form  coordination  bonds  with  the  
immobilized  transition  metal  (Co2+)  [14].  Using  a  Co2+  resin  can  capture  all  the  OB1  proteins  
since  they  all  have  a  His-tag  that  can  bind  to  the  matrix  whereas  other  proteins  may  not  be  able  
to.  
To  accomplish  this,  the  soluble  cell  lysate  was  filtered  onto  a  purification  column  with  5  
mL  of  Co 2+  resin  with  a  0.45  micrometer  filter.  Then  the  filtered  solution  was  incubated  with  the   
Co 2+  resin  at  4  celsius  for  25  minutes  with  shaking.  This  allows  the  his-tagged  OB1  to  bind  to  the  
  
matrix.  After  the  25  min  incubation,  the  remaining  solution  is  allowed  to  flow  through  the  
matrix.  This  flow  through  contains  all  the  soluble  proteins  that  do  not  bind  to  the  cobalt  matrix.  It  
is  however  possible  to  have  proteins  bind  to  the  matrix  through  nonspecific  interactions.  This  is  
because  proteins  containing  consecutive  histidines  or  metal-binding  motifs  that  are  not  OB1  can  
bind  to  the  matrix.  To  get  rid  of  these  proteins  the  matrix  is  washed  multiple  times  with  the  1x  
lysis  buffer  which  contains  0.01M  of  imidazole.  Imidazole  has  a  higher  affinity  for  Co 2+  than   
histidine,  thus  displacing  these  nonspecifically  bound  proteins  from  the  matrix.  This  imidazole  
concentration  is  too  low  to  displace  much  of  the  bound  OB1  since  the  protein  is  over  expressed.  
To  elute  OB1  off  the  column,  an  elution  buffer  with  0.5M  concentration  of  imidazole  is  used.  
This  effectively  displaces  much  of  the  OB1  to  collect.   
Lanes  7  and  8  in  figure  15  show  a  gel  sample  on  the  flowthrough  and  elution.  In  the  
flowthrough,  lane  7,  there  are  a  lot  of  proteins  since  these  are  all  proteins  that  do  not  bind  to  the  
matrix,  however  in  the  elution,  lane  8,  there  is  only  one  clear  band.  This  band  is  at  the  17.7  kDa  
mark  which  is  where  the  OB1  protein  should  be.  Now,  the  OB1  protein  has  been  isolated  from  
the  cell  material,  however  it  is  clear  that  the  elution  (which  contains  OB1)  is  contaminated  by  
other  proteins.  In  lane  8  there  are  multiple  bands  of  proteins  not  just  at  the  17.7  kDa  mark.  To  get  
rid  of  these  proteins  of  different  sizes  another  technique  called  size  exclusion  chromatography  
(SEM)  is  used.   
SEM  is  a  method  which  separates  the  proteins  within  the  elution  based  on  size.  To  
accomplish  SEM,  Fast  Liquid  Protein  Chromatography  (FPLC)  was  used.  The  FPLC  machine  is  
able  to  separate  a  protein  mixture  based  on  size  because  one  of  its  major  components  is  a  column  
that  consists  of  a  matrix  of  beads  in  which  the  spaces  between  them  gets  smaller  further  down.  
  
As  a  result,  bigger  proteins  come  off  the  column  first  while  smaller  proteins  come  off  later  since  
they  travel  further  through  the  matrix.   
To  use  the  FPLC  machine  a  FPLC  buffer,  specific  for  the  protein,  was  attached  to  the  
machine  (this  is  the  buffer  the  proteins  eluted  off  of).  The  protein  elution  was  then  concentrated  
down  to  5  mL  using  the  and  then  injected  into  the  FPLC  machine.  As  the  machine  runs,  it  
separates  out  the  proteins  within  the  5  mL.  To  quantify  the  amount  of  protein  coming  off  the  
column  as  time  passes,  the  separated  sample  runs  through  a  part  of  the  machine  that  measures  
UV  absorbance  at  280  nm.  At  this  wavelength,  aromatic  residues  within  the  proteins  absorb  the  
most  amount  of  light.  Thus,  the  amount  of  absorbance  at  280  nm  is  directly  related  to  the  amount  
of  protein  eluted.   
  
Figure  16  shows  the  UV  absorbance  chromatogram  of  the  FPLC  run  for  OB1.  The  very  first  
peak  of  proteins  coming  off  is  the  aggregate  peak  which  includes  any  aggregated  OB1  and  very  
  
large  proteins.  The  elution  at  80mL  is  where  OB1  came  off  the  column.  The  elution  was  
collected  in  2mL  fractions.  Figure  17  shows  an  
SDS-PAGE  gel  of  the  aggregate  peak  and  the  
elution  at  80  mLs.  The  gel  crealy  shows  that  the  
elution  contains  OB1  since  there  are  multiple  
bands  at  the  17.7  kDa  mark.   
  
To  calculate  the  concentration  of  OB1  that  
was  eluted.  The  protein  was  diluted  in  8M  
Guanidine  Hydrochloride  in  a  1:2  ratio  and  the  
absorbance  at  280  nm  was  captured.  The  molar  concentration  of  protein  was  then  calculated  
using  Beer-Lambert's  law:  A=ecl.  
The  concentration  of  OB1  is  12μM.  
OB2:  
The  same  process  to  purify  OB1  was  
used  to  purify  OB2  as  well.  Figure  18  
shows  the  SDS-PAGE  gel  of  the  
different  steps  within  the  purification  
process.  OB2  is  16.7  kDa,  and  the  
protein  is  present  in  the  post  
induction  (lane  3),  sonication  (lane  
4),  soluble  fraction  (Lane  5),  and  the  
elution  (lane  8).  
  
 Figure  19  shows  the  FPLC  chromatogram  of  OB2,  the  protein  elutes  at  around  80  mL  just   
like  OB1  which  makes  sense  since  both  proteins  are  very  similar  in  size.   
  
An  SDS-PAGE  gel  of  the  aggregate  peak  and  elution  is  shown  in  figure  21.  The  
fractions  eluted  at  80mL  show  that  
OB2  has  been  successfully  separated  
from  the  rest  of  the  solution.  
The  concentration  of  OB2  
was  calculated  the  same  way  as  OB1  
and  is  11μM.  
OB3:  
OB3  was  first  purified  using  
the  method  described  above.  Figure  
21  shows  the  SDS-PAGE  gel  for  the  
purification  of  OB3.  An  interesting  
  
thing  to  note  about  this  figure  is  the  OB3  is  present  in  the  post  induction  sample  (lane  3)  and  the  
sonication  sample  (lane  4)  which  is  as  
expected.  However  OB3  is  not  present  in  
the  soluble  or  insoluble  fractions  of  the  cell  
latsaye  (lanes  5  &  6).  The  most  possible  
explanation  for  this  is  that  OB3  is  actually  
in  the  insoluble  fraction.  Running  a  gel  
sample  for  the  insoluble  fraction  is  tough  to  
go  since  the  insoluble  pellet  needs  to  be  
resuspended  in  a  buffer.  Since  it  is  insoluble  
this  is  difficult  to  do.  But  the  fact  that  OB3  
was  not  present  in  the  soluble  fraction  
shows  that  it  most  likely  precipitated  out  of  solution.  
Because  OB3  is  a  sub-domain,  it  could  be  that  it  does  not 
fold  properly,  and  it  aggregates  out  of  solution.  
A  potential  fix  for  this  problem  is  to  go  about  
purifying  OB3  using  a  different  method.  This  new  method  
would  involve  denaturing  OB3  and  then  purifying  it  out  of  
solution.  Conceptually,  this  is  very  similar  to  a  normal  
purification  since  a  denatured  protein  still  has  an  exposed  
His-tag  that  can  bind  to  the  Co2+  resin.  Furthermore,  the 
same  buffers  are  used,  however  both  the  1x  Lysis  Buffer  
and  elution  buffer  contained  6M  GuHCl.  GuHCl  denature  
  
proteins  by  disputing  the  hydrogen  bonds  that  hold  a  protein's  secondary  structure.  As  a  result,  
denatured  proteins  are  much  more  soluble.  Figure  22  shows  an  SDS-PAGE  gel  of  the  purification  
of  OB3  under  denaturing  conditions.  OB3  is  now  present  in  all  the  steps  it  would  be  expected  to  
be  in.  OB3  is  present  in  post  induction  sample  (lane  2),  sonication  (lane  3),  soluble  cell  lysate  
fraction  (lane  4),  and  the  lution  (lane  7).  All  of  these  bands  are  at  the  16.8  kDa  mark  which  is  the  
size  of  OB3.   
Even  though  OB3  was  successfully  eluted  it  is  still  denatured.  To  renature  OB3,  the  
guanidine  was  slowly  removed  from  solution  using  a  dialysis  
tubing.   
The  elution  was  then  concentrated  to  5mL  and  then  loaded  
onto  the  FPLC  machine  for  size  exclusion.  Figure  23  shows  the  UV  
absorbance  chromatogram  of  the  FPLC  run  using  the  OB3  elution  
from  denaturing  purification  conditions.  OB3  should  have  eluted  at  
around  80  mL  (since  this  is  where  proteins  the  size  of  OB3  elute  on  
  
this  FPLC  column,  however  there  is  no  peak  there.  Figure  24  shows  an  SDS-PAGE  gel  of  the  
aggregate  peak  and  clearly  OB3  is  present  within  this  peak.  Since  OB3  aggregates  under  normal  
and  denaturing  conditions  OB3  is  too  unstable  to  be  purified.  
OB12:  
OB12  was  purified  under  normal  purification  conditions.  Figure  25  shows  the  
SDS-PAGE  gel  of  the  different  steps  within  the  purification  process.  OB12  is  a  35.7  kDa  protein  
and  boxed  in  red,  figure  25  shows  the  presence  of  OB12  in  each  step  of  purification.  Lane  5  
shows  the  gel  sample  of  the  insoluble  fraction  and  it  seems  that  much  of  the  OB12  protein  is  
present.  In  fact  there  is  no  OB12  present  in  the  elution,  showing  that  the  protein  was  lost  before  
the  elution  (potentially  in  the  insoluble  fraction).   
The  denaturing  protocol  using  6M  GuHCl  
was  not  used  because  OB12  is  too  large.  This  protocol  is  
only  recommended  for  
proteins  less  than  18  kDa  
since  proteins  bigger  than  this  
are  more  likely  to  improperly  
refold.  However,  to  
potentially  increase  the  yield  
of  OB12,  the  purification  was  
repeated  using  a  1.5M  salt  
concentration.  This  is  because  in  the  insoluble  fraction,  larger  
fragments  of  DNA  are  present.  Thus,  it  was  hypothesized  that  OB12  was  present  in  the  insoluble  
fraction  because  it  was  binding  to  DNA.  The  strength  of  protein  DNA  interactions  reduces  in  the  
  
presence  of  high  salt  concentration  due  to  lower  electrostatic  interactions.  However,  this  did  not  
increase  the  yield  of  OB12  as  it  still  was  not  present  in  the  elution  as  seen  in  the  last  lane  of  
Figure  26.   
OB123:  
OB123  was  first  purified  under  normal  conditions.  The  SDS-PAGE  gel  in  Figure  27  
shows  the  steps  of  the  OB123  purification.  This  protein  is  55  kDa,  however  there  are  no  clear  
bands  near  this  area  on  the  gel  indicating  that  OB123  was  not  successfully  purified.  In  fact,  the  
elution  (lane  7)  itself  does  not  contain  any  OB123  protein.  This  is  quite  surprising  since  it  was  
expected  that  OB123  would  be  more  stable  than  the  other  constructs  since  it  contains  all  
individual  domains.  
OB123  could  have  potentially  aggregated  thus  it  is  not  
binding  to  the  Co 2+  matrix.  Due  to  this  problem,  the   
denaturing  protocol  for  purifying  protein  using  6M  
GuHCl  was  used.  This  protocol  is  only  recommended  
for  proteins  that  are  less  than  18  kDa  in  size.  However  
since  sub  domains  
(like  the  individual  
OB  folds)  fold  
independently/separately  from  one  another,  it  was  hypothesized  
that  using  this  protocol  for  purifying  a  protein  as  big  as  OB123 
was  justifiable.  From  the  SDS-PAGE  gel  shown  in  Figure  28,  it  
  
is  evident  that  the  denaturation  purification  protocol  was  not  successful.  OB123  was  not  present  
in  the  elution  (or  any  other  lane).   
OB23:  
OB123  was  first  purified  under  normal  conditions.  The  SDS-PAGE  gel  in  Figure  29  
shows  the  steps  of  the  OB123  purification.  This  protein  is  55  kDa,  however  there  are  no  clear  
bands  near  this  area  on  the  gel  indicating  that  OB123  was  not  successfully  purified.  In  fact,  the  
elution  (lane  7)  itself  does  not  contain  any  OB123  protein.  However  due  to  time  constraints  




The  electrophoretic  mobility  shift  assay  
tests  the  DNA  binding  affinity  of  a  
protein  for  DNA.  Figure  30  shows  how  
these  assays  accomplish  this.  Each  lane  is 
loaded  with  DNA  and  increasing  
concentrations  of  protein.  The  protein  
binds  to  DNA,  and  as  a  result  it  has  a  
higher  molecular  weight  than  the  
unbounded  DNA.  Due  to  this  the  bands  
on  top  showed  DNA  bounded  by  protein  
while  those  on  the  bottom  show  unbounded  DNA.  Notice  that  the  bands  of  the  unbound  DNA  
  
get  lighter  and  the  bands  of  the  bounded  DNA  get  darker  as  the  concentration  of  protein  
increases.  This  is  what  should  be  expected.   
  
Figure  31shows  the  best  
EMSA  gel  that  this  study  could  
produce.  Unfortunately  there  is  Not  
as  much  separation  between  the  bands  
and  The  control  band  of  unbounded  
DNA  and  no  protein  is  not  present.  
However  the  binding  reactions  used  
to  make  this  gel  can  be  optimized  to  
produce  a  better  gel  with  a  higher  resolution.   
  
  
   
The  table  below  shows  the  binding  reaction  concentrations  for  this  gel.  The  methods  
section  describes  more  clearly  what  each  reagent  was.  Though  this  gel  is  not  ideal,  it  does  show  
that  OB1  does  bind  to  ssDNA  which  is  important  in  understanding  where  near  the  DSB  overhang  
the  protein  binds  to.   
Though  there  were  a  lot  of  optimization  steps  needed  to  get  the  EMSA  results  shown,  
improving  on  these  conditions  like  the  runtime  and  concentrations  of  the  DNA,  protein,  and  
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